Search for a trial

Liquid biopsy in prostate cancer

- special attention for the development and harmonization of the pre-analysis of liquid biopsy, for blood as well as urine, and next to this for ctDNA as well as ctRNA- special attention for the detection of AR-V7 in blood and urine- special…

Prostatic Artery Injection vs Intra-Venous Injectin of 18F-DCFPyL to evaluate treatment strategy in Prostate cancer

Primary Objective: • To evaluate the ability to concentrate the radiotracer in prostatic cancer lesions ( with respect to accumulation in background tissues) by prostatic artery injection (PAI), especially within the prostate gland compared to…

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic renal cell carcinoma (RCC) with a clear-cell component, who progressed…

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects with Advanced, Relapsed or Refractory Renal Cell Carcinoma (RCC) with Clear Cell Differentiation

Primary Objective, Part A: To assess the safety of a single escalating dose and multiple dose regimen of CTX130 in subjects with unresectable or metastatic ccRCCPrimary Objective, Part B (Cohort Expansion): To assess the efficacy of CTX130 in…

An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

This study has been transitioned to CTIS with ID 2023-503421-19-00 check the CTIS register for the current data. This study will evaluate the efficacy, safety, and PK of enfortumab vedotin in combination with pembrolizumab, with or without platinum-…

Prospective Bladder Cancer Infrastructure - An infrastructure for observational and interventional bladder cancer research

We propose to set up a bladder cancer infrastructure within the logistic framework of the NCR. Patients with HR-NMIBC, MIBC and mBC will be prospectively recruited for ProBCI with longitudinal assessments from primary diagnosis until death. Main…

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy

This study has been transitioned to CTIS with ID 2023-506146-23-00 check the CTIS register for the current data. Cohorts 1, 2, and 3 only:The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with…

A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent after treatment with BCG

Primary objectiveTo compare the event free survival per pathological review committee (PRC) of nivolumab plus BCG vs BCG alone in all randomized ParticipantsEFS, defined as the time from randomization until any of the following events: recurrence (…

A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer with Disease Progression or Recurrence Following Treatment with a Platinum Agent

Main objective:- Evaluate the anti-tumor activity per RECIST 1.1 in participants with metastatic or locally advanced/unresectable urothelial cancer treated with bintrafusp alfa. Secondary objectives: - Evaluate other measures of antitumor activity…

Contrast ultrasound dispersion imaging (CUDI) as a diagnostic modality in the diagnosis of renal cell carcinoma.

The main goal of this study is to assess whether CUDI-quantification of CEUS can successfully be correlated to malignant pathology results of kidney tissue.

PredicTive value of FluoR-18 PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT before PLND for lymph nodE staging in primary pRostate cancer

To evaluate diagnostic accuracy of PSMA-PET/CT and FACBC-PET/CT in detection of lymph node metastases in initial staging of intermediate- to high-risk PCa.

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

This study has been transitioned to CTIS with ID 2023-503500-87-00 check the CTIS register for the current data. This study is designed to assess the antitumor efficacy and safety of pembrolizumab + CRT following maximal TURBT compared with placebo…